Moderna (MRNA) Income from Continuing Operations (2017 - 2026)
Moderna (MRNA) reported Income from Continuing Operations of 1343000000.0 for Q1 2026, down 38.31% year-over-year from 2177050083.47 in Q1 2025, and down 62.59% quarter-over-quarter from 826000000.0 in Q4 2025.
Moderna (MRNA) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Moderna (MRNA) has 10 years of Income from Continuing Operations data on file, last reported at 1343000000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 1343000000.0, down 38.31% year-over-year; the trailing twelve-month figure through Mar 2026 was 3194000000.0 (up 4.86% YoY), and the FY2025 annual result was 2822000000.0, up 20.75% from the prior year.
- Income from Continuing Operations retreated to 1343000000.0 in Q1 2026 per MRNA's latest filing, from 826000000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 3657000000.0 in Q1 2022 and troughed at 3630000000.0 in Q3 2023.
- A 5-year average of 239882352.94 and a median of 825000000.0 in 2025 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations soared 199.51% in 2022, then plunged 1638.46% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 1465000000.0 in 2022, then plunged by 85.19% to 217000000.0 in 2023, then slumped by 616.13% to 1120000000.0 in 2024, then gained by 26.25% to 826000000.0 in 2025, then plunged by 62.59% to 1343000000.0 in 2026.
- Business Quant data shows MRNA's Income from Continuing Operations at 1343000000.0 in Q1 2026, 826000000.0 in Q4 2025, and 200000000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Moderna | 25.27 Bn | 20.06 Bn | -566.00 Mn | -1.34 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.34 Bn |
| Dec 31, 2025 | -826.00 Mn |
| Sep 30, 2025 | -200.00 Mn |
| Jun 30, 2025 | -825.00 Mn |
| Mar 31, 2025 | -971.00 Mn |
| Dec 31, 2024 | -1.12 Bn |
| Sep 30, 2024 | 13.00 Mn |
| Jun 30, 2024 | -1.28 Bn |
| Mar 31, 2024 | -1.18 Bn |
| Dec 31, 2023 | 217.00 Mn |
| Sep 30, 2023 | -3.63 Bn |
| Jun 30, 2023 | -1.38 Bn |
| Mar 31, 2023 | 79.00 Mn |
| Dec 31, 2022 | 1.47 Bn |
| Sep 30, 2022 | 1.04 Bn |
| Jun 30, 2022 | 2.20 Bn |
| Mar 31, 2022 | 3.66 Bn |
| Dec 31, 2021 | 4.87 Bn |
| Sep 30, 2021 | 3.33 Bn |
| Jun 30, 2021 | 2.78 Bn |